Program
onvuzosiran sodium
Also written as “ADX-324”, “ADX-324 Dose Level 1” and “ADX-324 Dose Level 2”.
Its studies are mostly in Angioedemas, Hereditary, led by ADARx Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| ADARx Pharmaceuticals | 33 open or running | phase 3since Apr 7, 2025 | Dec 16, 2022 | Nov 30, 2027phase 3 · NCT06960213 |
Also a collaborator on its studies: Avance Clinical Pty.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 16, 2022First study: phase 2 study in Angioedemas, HereditaryFirst studyNCT05691361 · 53 enrolled · Australia
- Apr 7, 2025Phase 3 study in Angioedemas, HereditaryNCT06960213 · 90 planned · United States, Argentina, Australia and more
- Feb 19, 2026Phase 3 study in Angioedemas, HereditaryNCT07428499 · 90 planned · United States, Argentina, Australia and more
Ahead
- Nov 30, 2027Primary completion: phase 3 study in Angioedemas, HereditaryNCT06960213
- Dec 31, 2027Primary completion: phase 2 study in Angioedemas, HereditaryNCT05691361
- Jun 30, 2030Primary completion: phase 3 study in Angioedemas, HereditaryNCT07428499
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07428499Angioedemas, Hereditary · United States, Argentina, Australia and more | 3 | Recruiting | Jun 30, 2030 | 90 |
| NCT06960213Angioedemas, Hereditary · United States, Argentina, Australia and more | 3 | Recruiting | Nov 30, 2027 | 90 |
| NCT05691361Angioedemas, Hereditary · Australia | 2 | Active, not recruiting | Dec 31, 2027 | 53 |
How it is read
Names in the registry
- “ADX-324”, 2 entries
- “ADX-324 Dose Level 1”, 1 entry
- “ADX-324 Dose Level 2”, 1 entry
Conditions, from the studies’ own filings
- Angioedemas, Hereditary, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.